Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.47 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.47 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.38 |
| ▸ | TGM2 | P21980 | 1/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CCR6 | P51684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612209 | 0.92 | MAPT (0.65) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL1393073 | 0.89 | MAPT (0.60) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL17054792 | 0.83 | MAPT (0.68) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL17055159 | 0.82 | MAPT (0.62) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL31586676 | 0.81 | MAPT (0.61) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL23104443 | 0.81 | MAPT (0.60) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL17055328 | 0.80 | MAPT (0.56) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL18053948 | 0.79 | MAPT (0.70) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL21245532 | 0.79 | MAPT (0.62) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL31303379 | 0.79 | MAPT (0.62) | MAPTPOLBRAB9ASMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | NUVATION BIO INC (US) | 2023-03-02 | — | — | US | disclosed |
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | NUVATION BIO INC. (US) | 2021-11-16 | — | — | US | disclosed |
| CN-112334451-A | Heterocyclic compounds as kinase inhibitors | 诺维逊生物股份有限公司 | 2021-02-05 | — | — | CN | disclosed |
| EP-3752491-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | Nuvation Bio Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| WO-2019161224-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | GiraFpharma LLC (US) | 2019-08-22 | — | — | WO | disclosed |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-08-15 | — | — | US | disclosed |
| US-20080221107-A1 | Therapeutic Agents | ASTRAZENECA AB (SE) | 2008-09-11 | — | — | US | disclosed |
| EP-1907398-A1 | THERAPEUTIC AGENTS | AstraZeneca AB (SE) | 2008-04-09 | — | — | EP | disclosed |
| WO-2007011284-A1 | THERAPEUTIC AGENTS | ASTRAZENECA AB (SE) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11174252-B2 | Heterocyclic compounds as kinase inhibitors | CDK6, CDK4, CDK9 | MAPT 3390/4885POLB 921/4885RAB9A 1978/4885 |
| US-20190248774-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | MAPT 3156/4885POLB 1065/4885RAB9A 2664/4885 |
| US-20080221107-A1 | Therapeutic Agents | HTT, ACHE, GRIN2A | MAPT 22/4885POLB 1714/4885RAB9A 822/4885 |
| US-20230062022-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | CDK4, CDK6, CDK8 | MAPT 3156/4885POLB 1065/4885RAB9A 2664/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.